Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: Other
Life Threatening? No
Write-up: Information has been received from SPMSD (manufacturer control# DK-1577272925-2016007285) on 13-JUL-2016. Case received from a physician via HA on 11-Jul-2016 under the reference number DK-DKMA-WBS-0003980. A 16-year-old female adolescent patient received GARDASIL (batch number lot unknown, Dose 1) via intramuscular route on 08-Oct-2008, GARDASIL (batch number Lot unknown, dose 2) via intramuscular route on 06-Jan-2009, GARDASIL (batch number Lot number, Dose 3) via intramuscular route on 14-May-2009. The patient experienced Syncope (2010), Dizziness (2010) and on an unknown date: Headache, palpitation, nausea, abdominal pain, obstipation, diarrhea, skin disorder, fatigue, cognitive disorder, involuntary muscle movement, temperature regulation disorder, joint pain, muscle pain, dry eyes, dry mouth and absence from high school due to sickness on an unknown date. The patient''s outcome was reported as Not Recovered/Not Resolved. Translated narrative: The patient reports that the symptoms started within the first year of all vaccinations. Her first symptoms were syncope and dizziness. The other symptoms have developed subsequently. At the time of vaccination, she had a normal activity level - she went swimming and boxing 3 times per week in total and to the scouts. As a consequence of her many symptoms, she had been absent from high school for sickness. The tilt-table test showed that she does not fulfill diagnostic criteria for Postural Orthostatic Tachycardia Syndrome.
Copyright © 2018 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166